Insulet Recalls 7 Million Omnipod Pods Due to Insulin Under-Delivery Risk — Insulet Corporation

Event summary

Insulet voluntarily recalled ~7 million Omnipod Pods (Omnipod 5, DASH, Eros) due to a manufacturing defect causing potential insulin under-delivery.
The issue stems from a small tear in the tubing (cannula), leading to 24 reported serious adverse events, including hospitalization and DKA.
Affected Pods represent ~8.5% of 2025 global Omnipod Pod production, with ~60% of the recalled units already consumed or expired.
Insulet has identified the cause and implemented corrective actions, offering free replacements for affected customers.
The recall does not impact continuous glucose monitoring (CGM) systems or readings.

The big picture

This recall highlights ongoing challenges in medical device manufacturing, particularly in ensuring consistent quality in automated insulin delivery systems. The incident underscores the critical need for robust quality control in diabetes management technology, where device failures can have severe health consequences. Insulet’s ability to manage this crisis will be closely watched by investors and regulators alike.

What we're watching

Regulatory Scrutiny: How the FDA and other regulators will respond to this recall, particularly given the serious adverse events reported.
Operational Impact: Whether Insulet can sustain production and supply chain stability while implementing corrective actions.
Market Confidence: The pace at which customer trust in Omnipod systems may be restored following this recall.